Latest Investments News

GQG Partners reported a rise in Funds Under Management to USD 165.7 billion as of January 2026, buoyed by strong investment performance despite notable net outflows during the month.

AGL Energy reported a steady half-year performance with flat EBITDA and a slight dip in net profit, underpinned by improved operational metrics and strategic moves including a major telco divestment and renewable investments.

Evolution Energy Minerals has announced a $4 million renounceable entitlement offer priced at 1.5 cents per share, including free attaching options, with major shareholder Metals One Plc committing $1 million.

BPM Minerals has raised A$3.5 million in a placement anchored by Terra Capital and Tribeca Investment Partners to accelerate exploration at its promising Forelands Gold Project in Western Australia.

AGL Energy reported a steady first half with flat underlying EBITDA and a narrowed FY26 earnings outlook, while accelerating its renewable projects and forming a strategic partnership with Aussie Broadband.

St Barbara Limited reports solid progress on key transactions with Lingbao Gold Group and Kumul Mineral Holdings, aiming to complete deals and trigger a Final Investment Decision for the New Simberi Gold Project by the end of March 2026.

AGL Energy Limited has announced a fully franked ordinary dividend of AUD 0.24 per share for the six months ending December 2025, payable in March 2026. This dividend reflects the company’s steady financial footing amid ongoing market challenges.

Killi Resources has identified a significant gold-copper-molybdenum geochemical anomaly at its Mt Rawdon West Project in Queensland, marking a key milestone with new high-priority drill targets.

ASB’s half-year results show a modest 1% rise in cash net profit, driven by growth in home, business, and rural lending alongside a 5% increase in customer deposits. The bank is investing heavily in technology, customer experience, and social housing initiatives to support New Zealand’s long-term prosperity.

Noxopharm Limited has secured a major scientific milestone with the publication of its Sofra™ platform research in Nature Immunology, highlighting a novel anti-inflammatory mechanism with broad therapeutic potential.

Argenica Therapeutics has reported a significant increase in its half-year loss to $3.82 million, driven by reduced revenue and higher research and development expenses. The company continues to invest heavily in its neuroprotective drug candidate ARG-007 amid ongoing clinical trials.

AGL Energy reported a 42% drop in statutory profit for the half-year ended December 2025, despite a modest revenue decline and growth in customer services. The company declared a higher interim dividend, underscoring confidence amid operational challenges and a strategic pivot to renewables.